List view / Grid view
Approval of the first treatment for patients one year old…
Approval of the first treatment for patients one year old and over with eosinophilic esophagitis (EoE) was based on trial data showing a greater proportion of children given Dupixent achieved histological remission compared to placebo.
Dupixent® has been approved by European Commission as the first…
Dupixent® has been approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis.
Dupixent®, the first and only targeted medicine for prurigo nodularis…
Dupixent®, the first and only targeted medicine for prurigo nodularis has been approved by the EC for adults with a moderate-to-severe form of the condition.
Dupixent® reduced eosinophilic oesophagitis symptoms by 64 percent compared to…
Dupixent® reduced eosinophilic oesophagitis symptoms by 64 percent compared to placebo and met primary endpoints in second Phase III study.
